Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
33.27
-1.94 (-5.51%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 33.16 - 35.43
52 week 29.71 - 43.00
Open 35.02
Vol / Avg. 3.33M/2.85M
Mkt cap 8.92B
P/E 52.07
Div/yield     -
EPS 0.64
Shares 283.82M
Beta 1.12
Inst. own 98%
Apr 27, 2016
Q2 2016 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 16, 2016
Hologic Inc at Barclays Global Healthcare Conference - 4:20PM EDT - Add to calendar
Mar 9, 2016
Hologic Inc at Cowen Health Care Conference - 10:00AM EST - Add to calendar
Mar 8, 2016
Hologic Inc at Raymond James Institutional Investors Conference - 9:15AM EST - Add to calendar
Mar 2, 2016
Hologic Inc Annual Shareholders Meeting (Estimated) - 8:30AM EST - Add to calendar
Mar 2, 2016
Hologic Inc Annual Shareholders Meeting - 8:00AM EST - Add to calendar
Feb 23, 2016
Hologic Inc at RBC Capital Markets Healthcare Conference - 11:00AM EST - Add to calendar
Feb 10, 2016
Hologic Inc at Leerink Partners Global Healthcare Conference - 3:05PM EST - Add to calendar
Jan 27, 2016
Q1 2016 Hologic Inc Earnings Call
Jan 27, 2016
Q1 2016 Hologic Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 12.21% 4.87%
Operating margin 18.14% 14.51%
EBITD margin - 36.04%
Return on average assets 4.44% 1.64%
Return on average equity 16.04% 6.35%
Employees 5,290 -
CDP Score - -

Address

250 Campus Dr
MARLBOROUGH, MA 01752-3020
United States - Map
+1-508-2632900 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Company’s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Officers and directors

Stephen P. MacMillan Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 46
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 72
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claus Egstrand Senior Vice President, General Manager - International
Age: 53
Bio & Compensation  - Reuters
Allison Bebo Senior Vice President - Human Resources
Bio & Compensation  - Reuters
John Griffin General Counsel
Bio & Compensation  - Reuters
Elaine S. Ullian Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
Jonathan N. Christodoro Independent Director
Age: 39
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 61
Bio & Compensation  - Reuters